%PDF-1.4
%
48 0 obj
<>
endobj
45 0 obj
<>
endobj
98 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-11-27T11:57:03Z
2024-03-28T09:33:12-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T09:33:12-07:00
application/pdf
Heather
2003-654.jan
uuid:62556230-1dd2-11b2-0a00-5308278d5b00
uuid:62556233-1dd2-11b2-0a00-1e0000000000
endstream
endobj
34 0 obj
<>
endobj
35 0 obj
<>
endobj
49 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 22 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/Properties<>>>/Rotate 0/Thumb 24 0 R/Type/Page>>
endobj
8 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 26 0 R/Type/Page>>
endobj
11 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 28 0 R/Type/Page>>
endobj
113 0 obj
[117 0 R]
endobj
114 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc -0.03101 Tw 10 0 0 10 66 713.1616 Tm
[(V)110.8 (arying proportions of patients with RA)-164.2 (are classified \322in)]TJ
0.1541 Tw -1.2 -1.2 Td
[(remission\323 depending on the definition chosen. )17.7 (The )54.8 (ACR)]TJ
0 Tw 0 -1.2 TD
(definition)Tj
0 Tc 6.5 0 0 6.5 92.8794 692.4616 Tm
(1)Tj
-0.00011 Tc 0.3291 Tw 10 0 0 10 101.9203 689.1616 Tm
[(is quite restrictive and few patients qualify)64.8 (.)]TJ
0.0264 Tw -4.792 -1.2 Td
[(V)110.8 (ariations of the )54.8 (ACR definition and dif)17.7 (ferent cutof)17.7 (f values)]TJ
0.02271 Tw T*
(for DAS, DAS-28, and DAS-28-3 are less restrictive and in)Tj
0.1055 Tw T*
(some studies up to 23% of patients were in \322remission\323)Tj
-0.0567 Tc 0 Tw 6.5 0 0 6.5 285.3689 656.4615 Tm
(11)Tj
0 Tc 10 0 0 10 291.5001 653.1616 Tm
(.)Tj
-0.00011 Tc 0.0042 Tw -23.75 -1.2 Td
(The major benefit of the precise definitions proposed by the)Tj
0 Tc 0.0309 Tw T*
[(US Food and Drug )54.9 (Administration)]TJ
0 Tw 6.5 0 0 6.5 193.5547 632.4615 Tm
(25)Tj
-0.00011 Tc 0.0309 Tw 10 0 0 10 200.0547 629.1616 Tm
(, e.g., complete clinical)Tj
0.0489 Tw -14.6055 -1.2 Td
(response, remission, and major clinical response, and those)Tj
0.328 Tw T*
(proposed in this issue by Balsa, )Tj
/T1_1 1 Tf
0.3279 Tw 14.8266 0 Td
(et al)Tj
/T1_0 1 Tf
-0.0567 Tc 0 Tw 6.5 0 0 6.5 223.0402 608.4615 Tm
(11)Tj
-0.00011 Tc 0.328 Tw 10 0 0 10 229.1715 605.1616 Tm
(, is to provide)Tj
0.0985 Tw -17.5171 -1.2 Td
(everyone with a common vocabulary to describe the same)Tj
0.2973 Tw T*
(clinical condition. In addition, these definitions provide)Tj
0.00349 Tw T*
[(tangible tar)17.7 (gets for drug developers who may gain commer-)]TJ
0.32761 Tw T*
(cial advantage when they can claim that their product)Tj
0.0847 Tw T*
(produces more or better remissions than their competitors\325)Tj
0.02769 Tw T*
[(products. )17.7 (Therapeutic progress evolves from this disorderly)]TJ
0.34241 Tw T*
(competitive process, but one must carefully assess the)Tj
0.02499 Tw T*
(precise definitions of the claimed \322remissions.\323 )Tj
/T1_2 1 Tf
10.022 -2.4 Td
[(HAROLD E. P)73.9 (AULUS, )]TJ
/T1_0 1 Tf
0 Tw 6 0 0 6 257.2802 485.1616 Tm
(MD,)Tj
0.02499 Tw 8 0 0 8 154.2205 475.1616 Tm
(Professor of Medicine,)Tj
0 -1.25 TD
[(UCLA)-220.2 (School of Medicine,)]TJ
T*
[(Division of Rheumatology)64.8 (,)]TJ
0 Tc T*
[(1000 )17.8 (V)110.9 (eteran )54.9 (A)74 (venue, Room 32-59,)]TJ
-0.00011 Tc T*
[(Los )54.8 (Angeles, California 90095-1670, USA)]TJ
/T1_1 1 Tf
-12.5276 -2.5 Td
[(Addr)36.8 (ess r)36.8 (eprint r)36.8 (equests to Dr)110.7 (. Paulus.)]TJ
/T1_2 1 Tf
0 Tw 10 0 0 10 54 391.1616 Tm
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 61 381.1616 Tm
[(1.)-875.1 (Pinals RS, Baum J, Bland J, et al. Preliminary criteria for clinical)]TJ
1.675 -1.25 Td
[(remission in rheumatoid arthritis. )54.8 (Arthritis Rheum )]TJ
0 Tc 0 Tw T*
(1981;24:1308-15.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(2.)-875.1 (American College of Rheumatology )54.8 (Ad Hoc Committee on Clinical)]TJ
1.675 -1.25 Td
(Guidelines. Guidelines for the management of rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 1996;39:713-22.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (Felson DT)73.9 (, )54.8 (Anderson JJ, Boers M, et al. )54.8 (American College of)]TJ
1.675 -1.25 Td
(Rheumatology preliminary definition of improvement in )Tj
T*
[(rheumatoid arthritis. )54.8 (Arthritis Rheum 1995;38:727-35.)]TJ
-1.675 -1.25 Td
[(4.)-875.1 (V)110.8 (erbur)17.7 (g RJ, van den Hoogen FHJ, Schattenber)17.7 (g )54.8 (A)128.9 (VMB, et al. High)]TJ
1.675 -1.25 Td
(dose cyclophosphamide followed by autologous stem cell )Tj
T*
(transplantation for the treatment of intractable rheumatoid arthritis)Tj
T*
[([abstract]. )54.8 (Arthritis Rheum 2000;43 Suppl:S-290.)]TJ
-1.675 -1.25 Td
[(5.)-875.1 (Edwards JCW)91.7 (, Cambridge G. Sustained improvement in )]TJ
1.675 -1.25 Td
(rheumatoid arthritis following a protocol designed to deplete B)Tj
T*
[(lymphocytes. Rheumatology Oxford 2001;40:205-1)36.8 (1.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (van Gestel )54.8 (AM, Prevoo MLL, van\325)17.7 (t Hof MA, van Rijswijk MH,)]TJ
1.675 -1.25 Td
(van de Putte LBA, van Riel PLCM. Development and validation of)Tj
T*
[(the European League )54.8 (Against Rheumatism response criteria for)]TJ
T*
[(rheumatoid arthritis. )54.8 (Arthritis Rheum 1996;39:34-40.)]TJ
-1.675 -1.25 Td
[(7.)-875.1 (Prevoo ML, van\325)17.7 (t Hof MA, Kuper NH, van Leeuwen MA, van de)]TJ
1.675 -1.25 Td
(Putte LB, van Riel PL. Modified disease activity scores that include)Tj
T*
(28-joint counts. Development and validation in a prospective )Tj
T*
[(longitudinal study of patients with rheumatoid arthritis. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1995;38:44-8.)Tj
-0.00011 Tc 31.325 71.671 Td
[(8.)-875.1 (Fries JF)79.7 (, Spitz P)110.7 (, Kraines RG, Holman HR. Measurement of patient)]TJ
1.675 -1.25 Td
[(outcome in arthritis. )54.8 (Arthritis Rheum 1980;23:137-45.)]TJ
-1.675 -1.25 Td
[(9.)-875.1 (Sharp JT)73.9 (, Lidsky MD, Collins LC, Moreland LJ. Method of scoring)]TJ
1.675 -1.25 Td
(the progression of radiologic changes in rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 1971;14:706-20.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (Larsen )54.8 (A, Dale K, Eek M. Radiographic evaluation of rheumatoid)]TJ
2.175 -1.25 Td
[(arthritis and related conditions by standard reference films. )54.8 (Acta)]TJ
T*
(Radiol Diagn 1977;18:481-91.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Balsa )54.8 (A, Carmona L, Gonz\207lez-\347lvaro I, Belmonte MA, )17.7 (T)35 (ina X,)]TJ
2.1381 -1.25 Td
[(Sanmart\222 R. )17.7 (V)110.8 (alue of DAS-28 and DAS 28-3 as compared to )]TJ
T*
(ACR-defined remission in rheumatoid arthritis. J Rheumatol)Tj
0 Tc 0 Tw T*
(2004;31:40-6.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12.)-875.1 (Prevoo MLL, van Gestel )54.8 (AM, van\325)17.7 (t Hof MA, van Rijswijk MH,)]TJ
2.175 -1.25 Td
(van de Putte LBA, van Riel PLCM. Remission in a prospective)Tj
T*
[(study of patients with rheumatoid arthritis. )54.8 (American)]TJ
T*
[(Rheumatology )54.8 (Association preliminary remission criteria in relation)]TJ
T*
[(to the disease activity score. Br J Rheumatol 1996;35:1)36.7 (101-5.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Short CL, Bauer )17.7 (W)91.8 (,)-0.1 ( Reynolds )17.7 (WE. Rheumatoid arthritis.)]TJ
2.175 -1.25 Td
(Cambridge: Harvard University Press; 1957.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Paulus HE, Di Primeo D, Sharp JT)73.9 (, et al. Patient retention and)]TJ
2.175 -1.25 Td
(hand-wrist radiograph progression of rheumatoid arthritis during a)Tj
T*
(3-year prospective study that prohibited DMARD. J Rheumatol)Tj
T*
(2004;31 \(in press\).)Tj
-2.175 -1.25 Td
[(15.)-875.1 (W)39.8 (illiams HJ, University of Utah Medical Center)54.8 (. Personal )]TJ
0 Tw 2.175 -1.25 Td
(communication.)Tj
0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (W)39.8 (illiams HJ, )54.8 (Alarc\227n GS, Joks R, et al. Early undif)17.7 (ferentiated)]TJ
2.175 -1.25 Td
[(connective tissue disease \(CTD\). )17.7 (VI. )54.8 (An inception cohort after 10)]TJ
T*
(years: disease remissions and changes in diagnoses in )Tj
T*
[(well-established and undif)17.7 (ferentiated CTD. J Rheumatol)]TJ
0 Tc 0 Tw T*
(1999;26:816-25.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875.1 (W)79.9 (olfe F)79.7 (, Ross K, Hawley DJ, Roberts FK, Cathey MH. )17.7 (The )]TJ
2.175 -1.25 Td
[(prognosis of RA)-220.2 (and undif)17.7 (ferentiated polyarthritis syndrome in the)]TJ
T*
[(clinic: a study of 1)36.8 (141 patients. J Rheumatol 1993;20:2005-9.)]TJ
-2.175 -1.25 Td
[(18.)-875.1 (W)79.9 (olfe F)79.7 (, Hawley DJ. Remission in rheumatoid arthritis. )]TJ
2.175 -1.25 Td
(J Rheumatol 1985;12:245-52.)Tj
-2.175 -1.25 Td
[(19.)-875.1 (Paulus HE. Unpublished data.)]TJ
T*
[(20.)-875.1 (Sokka )17.7 (T)74 (, Pincus )17.7 (T)74 (. Most patients receiving routine care for )]TJ
2.175 -1.25 Td
(rheumatoid arthritis in 2001 did not meet inclusion criteria for most)Tj
T*
[(recent clinical trials or )54.8 (American College of Rheumatology criteria)]TJ
T*
[(for remission. J Rheumatol 2003;30:1)36.8 (138-46.)]TJ
-2.175 -1.25 Td
[(21.)-875.1 (Lindqvist E, Saxne )17.7 (T)74 (, Geborek P)110.7 (, Eberhardt K. )17.7 (T)69.9 (en year outcome in)]TJ
2.175 -1.25 Td
(a cohort of patients with early rheumatic arthritis: health status,)Tj
T*
[(disease process and damage. )54.8 (Ann Rheum Dis 2002;61:1055-9.)]TJ
-2.175 -1.25 Td
[(22.)-875.1 (Fantini F)79.7 (, Gerloni )17.7 (V)128.9 (, Gattinara M, Cimaz R, )54.8 (Arnoldi C, Lupi E.)]TJ
2.175 -1.25 Td
(Remission in juvenile chronic arthritis: a cohort study of 683)Tj
T*
(consecutive cases with a mean 10 year follow-up. J Rheumatol)Tj
0 Tc 0 Tw T*
(2003;30:579-84.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(23.)-875.1 (Flato B, Lien G, Smerdel )54.8 (A, et al. Prognostic factors in juvenile)]TJ
2.175 -1.25 Td
(rheumatoid arthritis: a case-control study revealing early predictors)Tj
T*
(and outcome after 14.9 years. J Rheumatol 2003;30:386-93.)Tj
-2.175 -1.25 Td
[(24.)-875.1 (Oen K, Malleson PN, Cabral DA, Rosenber)17.7 (g )54.8 (AM, Petty RE,)]TJ
2.175 -1.25 Td
(Cheang M. Disease course and outcome of juvenile rheumatoid)Tj
T*
(arthritis in a multicenter cohort. J Rheumatol 2002;29:1989-99.)Tj
-2.175 -1.25 Td
[(25.)-875.1 (Food and Drug )54.8 (Administration. Guidance for industry)64.8 (. Clinical)]TJ
2.175 -1.25 Td
(development programs for drugs, devices and biological products)Tj
T*
(for the treatment of rheumatoid arthritis. US Department of Health)Tj
T*
(and Human Services, FDA, Feb 1999. [Internet; cited September)Tj
T*
[(25, 2003] )54.8 (A)74 (vailable from:)]TJ
0 Tw T*
[(http://www)64.8 (.fda.gov/cber/gdlns/rheumcln.htm.)]TJ
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2004; 31:1)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(4)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
28 0 obj
<>stream
8;Z\7MiP\/#ikr7OP`&m%CSi"dq$)H6fXuE]-Uj;+dr5J55)J0`o_FqBT!qXO&*gV
nT8s9]oVqi>D'&`G)0u:*;b^D$[7QK%>$9)#!Y>>qUjCZA$<Qk\o/D2,47&F1m)Mo79h+")q=OJ]H29!H2g4D*g-e@>g4[:N7eZDYcl,Id+<
)2ki$rbg+bUQ[Sc7q=lf:.&80bmH0Db2YIl!ZRPeV)_.PipY*;7'CNE-;o(XW(u%%
=Ekr,[THL+JBb,SN@D#Tg&*J71T>=JlpaG&X?0pQh4`,A97l??l'3mrpCbbu=r5U"
n9N[@&Z;cO-O`nsK.IKV!"3D#Vd'Hu@nthZtKbc+l$'=a+_#f!-0MB9pm[-<'N?@2uhDK1ejXar0eSC1>V?
j%6TY*)4CQqq/sgJ_@WJ`6#sXO-l?W<;etirg8*C!/?)D9`~>
endstream
endobj
32 0 obj
[/Indexed/DeviceRGB 255 31 0 R]
endobj
31 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
51 0 obj
<>
endobj
54 0 obj
<>
endobj
15 0 obj
<>
endobj
89 0 obj
<>
endobj
103 0 obj
<>
endobj
18 0 obj
<>
endobj
19 0 obj
<>stream
H\TPSWNHrtmncdZ_Xy,EE)jkDSH +*."ohk;uD[uuյ.uo<ހqv3gν
>P(p~Z45ƨKpr7FȍhS`Û7%ߋaG@ƼwO*ڶC3r톍ʉ3Âx5ܻ*ӌʤSZoRRLQeӦ):rrڤf6*&Jɨz4jZ13'C^TҦ3e7iӴ*F6ܽCZ p`@ 3%YJ ~,.D3'hK㩄O*JWNn?$6 K){d#Aaƿw&